Interpol is on the hunt for fugitives accused of such crimes as ivory smuggling. illegal logging, and trafficking live animals
The cosmetics retailer is facing a lawsuit
The oil market has moved beyond the Keystone XL pipeline
A new tool detects computer malware that’s watching your every move
The provider of high-interest business loans nears an IPO, on the strength of its data-powered credit analysis—and a network of shady brokers
Nike expects revenue from women to outpace its men's business.
Twist, stretch, twirl: a day in the life of a candy cane
Educational Credit Management, a guarantor and collector of student loans, wants to buy 56 campuses from Corinthian Colleges
The novelty items are hot for retailers large and small
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.